entertainment -WSS

entertainment

author：entertainment 2025-09-29 01:07:18 - browse：3961

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： How generative AI is inspiring dreams of a health data revolution

WSS

Amazon on where the company's health care bets are headed next

'Make People Better': The CRISPR babies story you probably don't know

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

RSV injection headlines need to be accurate for good uptake

Some top drug companies are starting to take action on climate

focus

entertainment

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Nobel honors Karikó and Weissman's enduring partnership

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A rare thyroid diagnosis led to unexpected, all

Hepatitis C has a cure — but many Americans still lack access to it

Nobel honors Karikó and Weissman's enduring partnership

Peter Hotez and the public health issue of online harassment

The United States is paying nearly triple for new Covid vaccines

Cancer drug shortages should be causing more outrage

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

explore

Health insurers' Q3 question: how much care are people getting?

The Karikó problem: Lessons for funding basic research

Why Novartis is changing the name of its research labs

NIH nominee Bertagnolli will get October confirmation hearing

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Some top drug companies are starting to take action on climate

hotspot

focus

focus

entertainment